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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• An unfavourable risk profile for myocardial
infarction (MI) is associated with various
lifestyle factors and co-morbidities that are
more prevalent among patients with severe
mental illness.
• Patient populations that are prescribed
antipsychotic agents have a higher
cardiovascular mortality rate than the
general population.
• The association between the use of
antipsychotic agents and any increase in the
risk of MI is unclear.
WHAT THIS STUDY ADDS
• The aim of this systematic literature review
was to assess the relationship between
antipsychotic agents and MI.
• Substantial clinical and methodological
heterogeneity between the five studies in
this review led to an inconclusive answer to
the question whether the use of
antipsychotics is associated with the
incidence of MI in adults.
• The largest study had a favourable internal
validity compared with the other studies
and did not find an association between the
use of antipsychotic agents and an
increased risk of MI.
AIM
Patient populations that are prescribed antipsychotic agents have
higher cardiovascular mortality rates. The risk of myocardial infarction is
influenced by various factors that are more prevalent in patients with a
mental illness. The aim of this review was to determine whether the
use of antipsychotic agents is associated with the incidence of
myocardial infarction in adults.
METHODS
Using multiple sources, all studies of antipsychotic agents using
myocardial infarction as primary or secondary outcome measures were
considered for inclusion. Study populations were adult subjects who
had been prescribed an antipsychotic agent at least once in their
medical history.
RESULTS
It total, five studies were identified. Four studies with small numbers of
events reported a moderate to strong effect of typical antipsychotic
agents on the risk of myocardial infarction. The largest study had a
favourable internal validity compared with all other studies and
reported no association between the risk of myocardial infarction and
current use of either atypical (relative risk 0.98, 95% confidence interval
[CI] 0.88, 1.09) or typical antipsychotic agents (relative risk 0.99, 95% CI
0.96, 1.03).
CONCLUSION
Clinical and methodological heterogeneity between the studies in this
review led to an inconclusive answer to the question whether the use
of antipsychotics is associated with the incidence of myocardial
infarction in adults. Whilst results conflicted, the largest study did not
find an association between the use of antipsychotic agents and an
increased risk of myocardial infarction.
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Objectives
Patient populations that are prescribed antipsychotic
agents have higher mortality rates than those of a repre-
sentative healthy comparison population [1–3].The excess
mortality in these patient groups can partly be attributed
to a two-fold higher cardiovascular death rate [1, 4–6]. The
observed over expected numbers of deaths from cardio-
vascular causes in patients with schizophrenia has
increased from 1.7 for both men and women in 1976–1980
to 8.3 for men and to 5.0 for women over a 20 year period
during which the use of antipsychotics has become more
widespread [7]. Patients experiencing psychoses and in
need of antipsychotic agents may be at a higher risk of
myocardial infarction (MI) regardless of any effect of anti-
psychotic medication [8–11]. An unfavourable risk profile
for MI is associated with various lifestyle factors and
co-morbidities that are more prevalent in patients with a
mental illness [12–16]. The association between the use of
antipsychotic agents and any increase in cardiovascular
morbidity or mortality is unclear, with some studies report-
ing increased risks for patients prescribed high doses of
antipsychotics whilst other studies have found no such
association [3, 17, 18].
This systematic review set out to perform an extensive
literature search on the association between antipsychot-
ics and MI and to summarize the findings of the individual
studies. The central research question in this systematic
review was:‘Is the use of antipsychotics associated with the
incidence of MI in adults?’
Methods
Data sources
Individual studies were identified using multiple sources.
Bibliographies used included Pubmed, Medline, Embase,
The Cochrane Library and Psychinfo. References of the
identified articles were used to track relevant articles not
identified in the original search. The searches were per-
formed by an epidemiologist (RB), initially in December
2009, with the main database searches updated in October
2010 and May 2011.The search strategy applied combined
the following terms:‘Antipsychotic* AND agents’ (this term
includes the following subheadings: ‘antipsychotic* AND
drugs’, ‘antipsychotic*, ‘major AND tranquilizers’, ‘neurolep-
tic* AND agents’, ‘neuroleptic*’, ‘tranquilizing AND agent’)
OR ‘Psychotropic*’ OR ‘Dopamine antagonist’ OR ‘Mental*
AND ill*’ OR ‘Psychot* AND ill*’ OR ‘Schizophrenia’ AND
‘Myocardial infarction’ OR ‘Coronary heart disease’. The
search was limited to studies of subjects aged 18 years or
over.
Inclusion and exclusion criteria
All therapeutic and aetiologic studies of antipsychotic
agents using MI as a primary or secondary outcome
measure were included. Study populations were all
patients who had been prescribed an antipsychotic agent
at least once in their medical history, allowing for studies to
measure ever, past, current and/or cumulative use of antip-
sychotics. If possible, depending on the studies identified,
secondary study populations were patients grouped by
psychiatric diagnoses. Studies had to compare therapy
with antipsychotic agents vs. no therapy, placebo or alter-
native medication and had to be at least 12 months in
duration. Studies comparing the efficacy and safety of dif-
ferent antipsychotic agents with each other have not been
included in this review.
Procedure
Information on key variables was collected to summarize
the individual studies and to make comparisons between
the studies. The result of interest was the effect of antipsy-
chotic agents on the incidence of MI, expressed as an odds
ratio (OR) or relative risk (RR) with 95% confidence intervals
(CIs). Information on both crude and adjusted results as
well as dose–response relationships and the results of rel-
evant sub-analyses concerning gender, age and history of
cardiovascular disease were all recorded.
Results
We identified two case-control studies, one nested case-
control study and two historic cohort studies using the
procedure shown in Figure 1 [19–23]. Three studies com-
pared the risk of MI amongst typical antipsychotic users
with the risk of MI in users of other psychotropic medica-
tions [19–21]. The two remaining studies investigated the
association between MI and the use of atypical antipsy-
chotics or typical antipsychotics or both vs. no use of antip-
sychotic agents [22, 23]. There was substantial clinical and
methodological heterogeneity between the studies (see
Table 1).
Detailed findings by study
Details and findings of the studies are summarized in
Table 2 and below.
Pratt et al. [21] conducted a historic cohort study of
United States survey data. The study population consisted
of a random group of interviewed household residents
divided in three categories: (i) individuals who had met the
criteria for Major Depressive Episode (MDE), (ii) individuals
with dysphoria and (iii) individuals without MDE or dys-
phoria. The 1551 subjects were originally part of a cohort
of 3481 Baltimore residents. The adjusted OR for ‘ever’ use
of phenothiazines was 2.92 (95% CI 1.23, 6.98).
A matched historic cohort study using data of a health
care company in the United States provided information
on the association between antipsychotic use and cardio-
vascular morbidity and mortality. Enger et al. [22] followed
11 400 cohort participants of whom 1920 were patients
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with schizophrenia using antipsychotics. The adjusted RR
for risk of MI amongst typical antipsychotic users (RR 5.34,
95% CI 1.75, 16.30) was higher than the adjusted RR for risk
of MI amongst atypical antipsychotic users (RR 1.66, 95% CI
0.19, 14.82) and the adjusted RR for risk of MI by current
typical and atypical antipsychotic use (RR 5.22, 95% CI 1.22,
22.40).
Thorogood et al. [19] conducted a matched case-
control study using national death certificates supplied by
the Office of Population Censuses and Surveys in Wales
and England to identify cases of fatal MI. One hundred and
sixty-one women were matched to 309 controls by age,
marital status and general practitioner. The RR for ever use
of a phenothiazine was 6.2 (95% CI 2.0, 19.1). The RR could
not be calculated for current use of phenothiazines (within
90 days of death) as none of the controls had experienced
the outcome of interest. The RR for ever use of thioxan-
thene was 4.6 (95% CI 0.90, 24) and higher than the RR for
current use of thioxanthene (RR 2.0, 95% CI 0.3, 14.2).
Penttinen & Valonen [20] conducted a nested case-
control study in Finland using cohort data of 3172 male
farmers who participated in a postal questionnaire con-
cerning working conditions, lifestyle and various diseases
and symptoms. Eighty-three men who experienced a MI
were identified via hospital discharge registries. These
cases were free of ischaemic heart disease at the start of
follow-up and were each matched to three controls by age,
smoking habit, social status and county of residence. The
OR for MI amongst ever users of neuroleptic agents was 1.5
(95% CI 0.40, 6.0).
A matched case-control study using national health
services registries in Denmark found no association
between a first-time hospitalization for MI and current or
former use of antipsychotic agents. Nakagawa et al. [23]
Unique titles indentified by
literature search using pre-
specified data sources and terms
(n=265)
 Closer examination of abstracts
(n=31)
 
Identification of further titles by
reference lists of relevant
studies (n=10)
 Full-text screening of potential
studies for inclusion (n=18)
 234 titles discarded because
titles did not refer to the
relationship of interest
Nineteen articles not considered
relevant for further investigation 
 Four further studies discarded
for full-text review after
scanning of abstracts 
 
 
13 studies excluded:
• 3 studies did not study MI as a
specific outcome;
• 7 studies did not analyze the
relationship between
antipsychotic agents and MI;
•3 studies did not include a
suitable control group
 Studies included in the current
review (n=5)
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matched 21 377 patients who were hospitalized with MI
with 106 885 controls by age, gender and county of resi-
dence. The adjusted RR for current conventional antipsy-
chotic use was 0.99 (95% CI 0.96, 1.03) and similar to the
adjusted RR for current atypical antipsychotic use (RR 0.98,
95% CI 0.88, 1.09).
Subgroup analyses
Subgroup-analyses were performed by Nakagawa et al.
[23]. The effect of antipsychotic agents on the risk of first-
time hospitalization of MI was not influenced by gender
(see Table 1), age or previous cardiovascular disease nor by
the cumulative number of daily-defined dosages [23].
Enger et al. found an inverse dose-response relation-
ship when the group with the smallest ratio of dispensed
days to total days (0–0.3] was used as a reference group
(see Table 2 [22]).
Between study comparisons
The definitions used to identify cases of MI differed widely.
MI was measured subjectively by Pratt et al. [21]. The rela-
tive validity and completeness of each objective source
differed. Nakagawa et al. included first-time hospitaliza-
tions for MI only, whereas Thorogood et al. [19] included
only fatal cases of MI. Penttinen & Valonen [20] used a mix
of incident cases of MI that were either hospitalized or had
died as a result of their MI. Enger et al. [22] included both
prevalent and incident cases of MI.
All studies used heterogeneous sources of medication
records and different types of medication. Thorogood
et al. [19] looked specifically into two types of conven-
tional psychotic agents (thioxanthene and phenothiaz-
ine). Pratt et al. [21] and Penttinen & Valonen [20] limited
the analysis to phenothiazines only and Nakagawa et al.
[23] and Enger et al. [22] grouped all typical and atypical
agents together. The recording of the date of starting and
stopping antipsychotic agents also differed between
studies. Pratt et al. [21] and Penttinen & Valonen [20] did
not measure the time of antipsychotic use and conse-
quentially no difference between current and past use
was made, nor was information given on cumulative
exposure.
Almost half of all the cohort members in the study by
Pratt et al. [21]had either died or were lost -to-follow-up
before the study had ended. Likewise, almost 40% of the
cohort members in the study by Enger et al. [22] had left
the claims database before the study ended. It is not
known what proportion of patients who ended their study
enrolment prematurely experienced an MI.
Three studies used heterogeneous study populations.
The indication for which patients received antipsychotic
treatment was not shown by Thorogood et al. [19], Pent-
tinen & Valonen [20] and Nakagawa et al. [23].The study by
Enger et al. [22] only included patients with schizophrenia
who were treated with antipsychotic agents and could not
control for the disease underlying the prescription of
Table 1
Methodological quality checklist of studies assessing the effect of antipsychotic use on the risk of myocardial infarction (MI) [31]
Methodological feature
Pratt
et al. [21]
Enger
et al. [22]
Thorogood
et al. [19]
Penttinen &
Valonen [20]
Nakagawa
et al. [23]
Sample of patients
Inclusion criteria defined? Yes Yes Yes Yes Yes
Sample selection explained? Yes Yes Yes Yes Yes
Adequate description of diagnostic criteria? Yes Yes Yes Yes Yes
Clinical and demographic characteristics fully described? Yes Yes No No Yes
Representative? No No No No Yes
Assembled at a common point in the course of their disease? No No Yes Yes Yes
Complete? No No Yes Yes Yes
Follow-up of patients
Sufficiently long? Yes Yes Yes Yes Yes
Outcome
Objective? No Yes Yes Yes Yes
Was the assessment blinded? No No No No No
Fully defined? No Yes Yes Yes Yes
Appropriate? Yes Yes Yes Yes Yes
Known for all or a high proportion of patients? No No Yes Yes Yes
Prognostic variable
Fully defined, including details of method of measurement? Yes Yes Yes Yes Yes
Precisely measured? No No No No No
Available for all or a high proportion of patients? No No Yes Yes Yes
Analysis
Statistical adjustment for all important prognostic factors? Yes Yes No No Yes
Treatment after inclusion in cohort
Fully described? No No N/A No N/A
Treatment standardized or randomized? No No N/A No N/A
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antipsychotics. Pratt et al. [21] adjusted for a history of
major depressive episode.
The studies by Thorogood et al. [19] and Penttinen &
Valonen [20] included only female subjects and male sub-
jects respectively and were published without the clinical
and demographic characteristics of the participants, limit-
ing the generalizability of their results.
The size of the study populations ranged from a few
hundred subjects to more than 100 000. The four studies
with the smallest number of events reported moderate to
strong effects of typical antipsychotic agents on the inci-
dence of MI [19–22]. The internal validity of the largest
study by Nakagawa et al. [23] compared favourably with all
other studies (see Table 2). Nakagawa et al. reported no
association between the use of any type of antipsychotic
agent and the experience of a MI [23].
Discussion
The aim of this systematic literature review was to assess
the relationship between antipsychotic agents and myo-
cardial infarction, a drug-event pair that has not been sys-
tematically reviewed previously. The five observational
studies that were the focus of this review conducted a
primary or secondary analysis addressing the research
question of interest.
The use of typical antipsychotics was associated with
an increase in the risk of MI in four studies with a small
number of events.Two studies investigated the association
between MI and the use of atypical antipsychotics and
found no association and a weak association respectively.
These results need to be interpreted with caution as the
estimates of effect size varied greatly between studies and
confidence intervals for these studies finding an effect
were wide. None of the studies reported a protective effect
of the use of antipsychotics on the risk of MI.
The review had several limitations. The review was
restricted to published studies written in English that
included adult populations. No randomized controlled
trials were identified. None of the studies provided infor-
mation with regard to the prescription of antipsychotic
agents via psychiatric services and there was a lack of infor-
mation with regard to treatment compliance. The study
populations in all five studies, the course of their diseases,
the source and type of medication, the covariates, the
study outcomes and study sizes differed substantially
between studies which may have influenced the differ-
ence in results between all five studies.
Between-study comparisons of studies conducted in
the early 1990s and those conducted more than a decade
later are likely to have been influenced by trends in MI
incidence and case-fatality as well as trends in the prescrip-
tion of antipsychotic medication and of medication for the
prevention and treatment of cardiovascular diseases. The
studies conducted in 1992 and 1996 could not include any
information on the use of atypical antipsychotic agents.
Residual confounding is likely to have influenced the
results of the studies conducted in 1992 and 1996 as the
adjustments of the crude associations were not as compre-
hensive as those made in later studies. Lifestyle factors
were not accounted for or through proxy variables in all
five studies. Three of the studies included in this review
were conducted amongst patients using antipsychotics
from the general population, whereas two studies specifi-
cally estimated a relative risk for MI in patients with schizo-
phrenia and MDE respectively. As severe mental illness in
general, and schizophrenia in particular, is associated with
both the prescription of antipsychotic agents and a
change in the risk of MI, the results of the individual studies
are likely to have been affected by confounding by indica-
tion [3, 22]. Any difference in risk of MI that is reported in
patient populations with a severe mental illness, who are
also prescribed antipsychotic agents, may not be causally
related to the use of the antipsychotic agent, but to factors
relating to the underlying disease.
Both typical and atypical agents increase the risk of
prolonged QT interval and torsades de pointes [24]. Obser-
vational studies using administrative data of patients who
are prescribed antipsychotic agents have found a two-fold
increase in risk of ventricular arrhythmias compared with
patient populations not taking antipsychotic agents [25,
26]. It is not known through which mechanism the use of
antipsychotics influences the risk of MI. Patient popula-
tions for whom antipsychotic agents are indicated differ
considerably from healthy comparison populations,
making it complicated to disentangle the various determi-
nants that influence the risk of MI in users of antipsychotics
[8–10, 27–29]. First time use of antipsychotics has been
associated with a change in risk markers for cardiovascular
events [30]. Any effect of antipsychotic agents on the risk
of MI could be mediated by risk factors of MI that are more
prevalent in patients suffering from psychoses.
Conclusion
Substantial clinical and methodological heterogeneity
between the studies in this review led to an inconclusive
answer to the question whether the use of antipsychotics
is associated with the incidence of MI in adults.The largest
study did not find an association between the use of antip-
sychotic agents and an increased risk of MI. Future studies
designed to investigate the coronary side-effects of antip-
sychotic agents are recommended, paying attention to the
strong possibility of confounding by indication. A case-
only approach such as the self-controlled case series may
be one solution; comparisons are made within individuals
who have both the event and exposure of interest and
therefore fixed confounders are completely controlled for.
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